Heather Christine Beckwith MD
Assistant Professor, Medicine, University of Minnesota Medical School, Minneapolis
Telehealth available
Request appointment909 Fulton Street Southeast2nd floorMinneapolis, MN 55455
Fax+1 612-676-4004
Overview of Dr. Beckwith
Dr. Heather Beckwith is an oncologist in Minneapolis, MN and is affiliated with multiple hospitals in the area, including M Health Fairview University of Minnesota Medical Center, M Health Fairview St. John's Hospital, and M Health Fairview Lakes Medical Center. She received her medical degree from Medical College of Wisconsin and has been in practice 20 years. She is one of 91 doctors at M Health Fairview University of Minnesota Medical Center and one of 22 doctors at M Health Fairview Lakes Medical Center who specialize in Oncology. She has more than 20 publications and over 500 citings.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2009 - 2012- University of MinnesotaResidency, Internal Medicine, 2006 - 2009
Medical College of WisconsinClass of 2006
Certifications & Licensure
MN State Medical License 2011 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
- A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer Start of enrollment: 2021 Mar 08
Roles: Principal Investigator
Publications & Presentations
PubMed
- Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.Mark Hensley, Justin Lengfeld, Steven Stoesz, Michelle Edwards, Franklin Pass
Frontiers in Oncology. 2025-01-01 - 16 citationsDatopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01 - 47 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: